NCT03810417View on ClinicalTrials.gov

Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI

PHASE4CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

July 22, 2019

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Acute Kidney Injury
Interventions
DRUG

Digoxin Antibodies Fab Fragments

Digoxin antibodies

OTHER

Placebo

Saline

DIAGNOSTIC_TEST

Baseline EO > 360 pM

Baseline ouabain concentration \> 360 pM

DIAGNOSTIC_TEST

EO < 360 pM

Baseline ouabain concentration \< 360 pM

Trial Locations (2)

21201

University of Maryland, Baltimore

21204

St Josephs Medical Center, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT03810417 - Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI | Biotech Hunter | Biotech Hunter